Sutent® 25 mg and 50 mg hard capsules: BfArM issues warning regarding counterfeits of the medicinal product from Romania
2014.06.17
Active substance: sunitinib
The Federal Institute for Medicinal Products and Medical Devices (BfArM) is circulating a warning against counterfeits of the 25 mg and 50 mg strengths of the cancer drug Sutent® produced by Pfizer. The counterfeits that are parallel imported can be identified based on visible differences in hard capsules and foil sealing of the plastic bottle.
risk information - full text (available in German only)